KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.32
+1.89%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$224.44M
MomentumView details →
1D Return
+1.89%
YTD Return
−44.77%
RSI (14)
55.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$224.44M
RSI (14)
55.0
MomentumView details →
1D Return
+1.89%
YTD Return
−44.77%
SummaryUpdated Jun 1, 2026
Keros Therapeutics, Inc. (NASDAQ:KROS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Lexington, Massachusetts. The company went public in April 2020 and focuses on developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. Keros operates in the specialized field of protein therapeutics and small molecule drugs, targeting conditions affecting blood cell production and bone health.
Similar companies
Latest newsMore news →
Dimensional Fund Advisors LP increased its stake in Keros Therapeutics, Inc. by 453.9% during the quarter, acquiring an additional 263,347 shares, as disclosed in a Form 13F filing.23d agoKeros Therapeutics reported a net loss of $28.7 million for Q2 2026, with zero revenue and diluted EPS of -$1.45, compared to a net loss of $30.7 million in Q2 2025.33d ago